1 / 12

MS/AL Radiation Oncology Research Partnership

MS/AL Radiation Oncology Research Partnership. W. Sam Dennis, MD, PhD P.I., Singing River Hospital System Sharon Spencer, MD P.I., University of Alabama – Birmingham Maggie Clarkson, RN, MS Grants Program Director, Singing River Hospital System. MS/AL RADIATION THERAPY RESEARCH PROGRAM

cicada
Download Presentation

MS/AL Radiation Oncology Research Partnership

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MS/AL Radiation Oncology Research Partnership W. Sam Dennis, MD, PhD P.I., Singing River Hospital System Sharon Spencer, MD P.I., University of Alabama – Birmingham Maggie Clarkson, RN, MS Grants Program Director, Singing River Hospital System

  2. MS/AL RADIATION THERAPY RESEARCH PROGRAM STAFFING PLAN SRHCC UABCCC P.I. – Dennis (10%)- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - P.I. - Spencer CO – P.I.GRANTS ADMIN (.5 FTE) PROGRAM DIRECTOR (1 FTE) Clarkson (3%) Hull (3%) Sariego (2.5%) Lyell (2.5%) RESEARCH STAFFOUTREACH STAFF (*)PATIENT NAVIGATORS Research Nurse (1 FTE) Health Educator/RN (1 FTE) Patient Advocate/Van Driver (2 FTE) Data Manager (1 FTE) CONTRACT: Biostatistician @ $5000.00/year * Shared oversight with Director, Community and Corporate Wellness Program

  3. Partnership/Mentor Relationship • Program Steering Committee • Scientific Review Committee • TeleSynergy programs • Investigator-initiated Studies • Workshops for investigators and grant staff • Medical and Support Staff training opportunities

  4. Clinical Research • Development of Activation Prioritization List for Cooperative Group Studies: RTOG, SWOG, NSABP, GOG, CTSU • Patient Population Data for SRHS-RCC reviewed against Active studies listings for study groups and: • Scientific questions of interest for medical staff • Standard treatment remains sub-optimal for site/stage • Treatment regimens inclusive of RT • Annual Accrual Goals • Long-term Clinical Research Office Goals

  5. SINGING RIVER HOPSITAL REGIONAL CANCER CENTER – OPEN CLINICAL TRIALS LIST ANAL/RECTAL RTOG 0315 A Randomized Double Blind Placebo-controlled Phase III Study to Determine the Efficacy of Sandostatin Lar Depot (Octreotide Acetate) in Preventing or Reducing the Severity of Chemoradiation-Induced Diarrhea in Patients with Anal or Rectal Cancer. (IRB ok 9/20/05)BREASTNSABP B-35 A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma In Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy (IRB ok 4/12/06)NSABP B-36 A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC) in Patients with Node-negative Breast Cancer (IRB ok 10/11/05)NSABP B-38 A Phase III, Adjuvant Trial Coparing Three Chemotherapy Regimens in Women with Node-positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-dense (DD) Doxorubicin/Cyclophosphamide followed by DD Paclitaxel (DD AC→P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC→PG) (IRB ok 10/11/05)SWOG S0221 Phase III Trial of Continuous Schedule AC + G vs. Every 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-operative Adjuvant Therapy in Node-positive or High-risk Node-negative Breast Cancer (IRB ok 10/11/05)COLONNSABP C08 A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin and Oxaliplatin (mFOLFOX6) every Two Weeks with Bevacizumab to the Same Regimen without Bevacizumab for the Treatment of Patients with Resected Stages II and III Carcinoma of the Colon. (IRB ok 9/20/05)LUNG SWOG S9925 SWOG S9925 Lung Cancer Specimen Repository Protocol, Ancillary (IRB ok 10/11/05) PROSTATE RTOG 0126 A Phase III Randomized Study of High Dose 3D-CRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer (IRB ok 9/20/05)

  6. Investigator-Initiated Studies • Phase I/II Trial of Alternative Dose Schedule of 1650cGy in 3 fractions for Palliative Radiation treatment of Bone Metastases • Development of Geriatric Assessment Profile to Support Accrual of Elderly Patients onto Clinical Research Trials • Impact of Cancer Screening Recruitment Model using Prior Participants as Advocates Among Minorities • ?? Immobilization Methods for Prostate IMRT • ?? Geriatric Oncology Issues

  7. Community Involvement Focus • Internal • Community & Corporate Wellness • Pharmacy/Social Services/Dietary/PT/OT/Financial Services • Transportation • External • Health-related Organizations • Faith-based Organizations • Business/Corporate • Civic/Community Service Organizations • Educational Institutions • Medical Community • Focus on Clinical Research Issues • Cancer Center referral base

  8. Patient Navigator Services • Team approach with oncologist/RN • Involvement post-treatment planning • Supportive needs assessments • Document categories of needs • Referrals to internal/external resources • Transportation assistance using van • Assist with Community Outreach programs • Monitor outcomes

  9. Community Outreach • Focus on minorities and underserved • Develop cancer control education/awareness/screening activities appropriate to specific target populations • Develop outcomes measures/monitoring methods to determine impact on participation in risk reduction activities • Develop ongoing cancer patient education programs and services for SRHS • Facilitate/coordinate support group activities • Support development of patient advocacy program

  10. Impact of Hurricane Katrina on Our Community:The Good, The Bad, the Ugly

More Related